Jacobs Journal of Cancer Science and Research

Safety and Effectiveness of Nimotuzumab in the Treatment of Advanced Head and Neck Cancer Patients. Phase IV Clinical Trial: Final Results

Published on: 2019-03-12

Abstract

Objective: Epidermal Growth Factor Receptor (EGFR) can be overexpressed in head and neck cancer (HNC). Nimotuzumab is a humanized monoclonal antibody (hMab) that binds to the EGFR. A phase IV study was conducted in advanced head and neck newly diagnosed and recurrent cancer patients to evaluate safety and efficacy of nimotuzumab.

Keywords

EGFR; HNC; Nimotuzumab; Monoclonal antibody;Chemotherapy; Radiotherapy; Safety; Survival